Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 07-Feb-2017

General Biotechnologies


We are developing a small molecule therapeutic to radically improve the treatment of metastatic cancers. Our compound — Nivien — inhibits several previously untargetable mechanisms within tumor cells that currently prevent medicines from effectively treating malignancies. Nivien is the first approach that utilizes both chemotherapy and immunotherapy to fight pancreatic cancer, which causes 300,000 deaths each year and has the highest mortality rate of all major cancers.


Additional Questions

Who is your customer?

Patients with metastatic pancreatic cancer and biopharma companies expanding their oncology portfolios.

What problem does this idea/product solve or what market need does it serve?

The current standard-of-care for metastatic pancreatic cancer yields a mean overall survival (mOS) of just 8.5 months. Our compound, Nivien, could dramatically enhance the efficacy of chemotherapy and immunotherapy in pancreatic tumors.

What attributes will make this idea/product successful? Why do you believe that those features will create success?

Our compound is able to inhibit previously untargetable tumor defense mechanisms that allow cancer to evade treatment. This is the first treatment that enables both chemotherapy and immunotherapy in pancreatic cancer, producing a synergistic therapeutic benefit.

Explain how you (your team) will execute to make this idea/product successful? What gives you (your team) an advantage over others already in the market or new to this market?

We have research experience in tumorigenesis and preclinical models for testing small molecules and have partnered with experts in oncology, preclinical drug development and pancreatic resistance to current therapies. With these partners and guidance from the FDA, we are working on the preclinical trials required for Investigational New Drug status. We also have strong and early IP covering both our current approach and potential alternatives.